GlassScriptPhysician profile
Stacy L Johnson
NPI 1548745334
$1,998.77
in general payments reported to CMS, 2019-2025
19 companies · $36.73 in 2025
The $36.73 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $598 · 2023: $501 · 2024: $140 · 2025: $36.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $544.78 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $406.60 | 2021-2024 | |
| Novo Nordisk INC | $209.44 | 2021-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $128.18 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $125.99 | 2021 | |
| Amgen INC. | $84.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.63 | 2021-2024 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $79.91 | 2021 | |
| Baxter Healthcare | $78.21 | 2022 | |
| Xeris Pharmaceuticals, INC. | $65.72 | 2022-2023 | Gvoke Hypopen, Keveyis |
| Dexcom, INC. | $48.79 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $34.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.96 | 2021-2022 | |
| Organon LLC | $18.67 | 2021 | |
| Boston Scientific Corporation | $15.95 | 2024 | Wavewriter Alpha Prime 16 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.41 | 2021 | |
| Nabriva Therapeutics, Plc | $12.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.09 | 2021 | |
| Surmodics, INC. | $8.29 | 2023 | Pounce Thrombectomy System, Pounce Venous Thrombectomy System, Pounce Thrombectomy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.